Phase 2 Dose-Ranging Efficacy and Safety Trial of SCH 900271 in Participants With Primary Hypercholesterolemia or Mixed Hyperlipidemia (P05675)

Inclusion Criteria: * Adults of either sex 18 to 75 years of age, inclusive, with a diagnosis of primary hypercholesterolemia (familial and nonfamilial) or mixed hyperlipidemia (increased LDL-C and triglycerides \[TG\]) * must be free of any clinically significant disease, other than primary hypercholesterolemia or mixed hyperlipidemia that would knowingly interfere with study evaluations * must be willing to adhere to dietary recommendations, protocol requirements, and provide written informed consent Exclusion Criteria: The participant will be excluded from entry if ANY of the criteria listed below are met: * use of any investigational drug within 30 days of study entry * female of childbearing potential or lactating * postmenopausal (or perimenopausal) woman who is currently experiencing hot flashes (e.g. within 30 days of study entry * homozygous familial hypercholesterolemia * congestive heart failure New York Heart Association (NYHA) Class III or IV * uncontrolled hypertension on or off therapy * cardiac arrhythmia requiring medication * clinical atherosclerotic disease that confers high risk for coronary heart disease (CHD) events (e.g. clinical CHD, symptomatic carotid artery disease, peripheral arterial disease, abdominal aortic aneurysm) * Type 1 Diabetes Mellitus * Type 2 Diabetes Mellitus * history of mental instability, drug/alcohol abuse or who has been treated or is being treated for severe psychiatric illness, which in the opinion of the investigator, may interfere with optimal participation in the study * gastrointestinal ulcer within 3 months of study entry * history of coagulopathy * history of gout * known active or chronic hepatic or biliary disease. * known significant impairment of renal function, dysproteinemia, nephrotic syndrome, or other renal disease * body mass index \>40 kg/m\^2 * taking non-steroidal anti-inflammatory drugs (NSAIDS) (acetaminophen and cyclooxygenase-2 \[COX-2\] inhibitors are allowed) * taking more than 100 mg aspirin per day * being treated with corticosteroids (oral, intramuscular, or intravascular) * more than 3 alcoholic beverages per day or its equivalent (one drink equals 1.5 ounces of 80 proof liquor or equivalent) during study participation